GEMCITABINE AND CAPECITABINE IN UNRESECTABLE OR METASTATIC CHOLANGIOCARCINOMA

本子项目是利用由NIH/NCRR资助的中心赠款提供的资源的众多研究子项目之一。子项目和研究者（PI）可能已经从另一个NIH来源获得了主要资金，因此可以在其他CRISP条目中表示。列出的机构是中心的，不一定是研究者的机构。这项研究的目的是找出卡培他滨和吉西他滨药物联合使用对肿瘤的影响（好的和坏的）。之所以进行这项研究，是因为目前还没有针对这种癌症的治愈方法。在不能切除的胆囊或胆管癌患者中，标准化疗使肿瘤缩小10%-15%，但这些反应只持续3-6个月。需要更好的治疗方法来治疗这种疾病的患者。病人将被要求提交他们的组织样本和血液样本，以便进行研究。科学家将研究他们的组织，看看是否能通过检测肿瘤组织的某些方面来预测他们的生存。如果他们同意，他们在登记参加这项研究之前所做的活检留下的肿瘤组织将被用于这些测试。在开始治疗前将采集血样。使用样本进行研究的同意书上有关于使用他们的组织进行研究的信息，并询问他们是否同意允许我们保留一些剩下的组织并将其用于未来的研究。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The purpose of this study is to find out what effect (good and bad) the combination of the drugs capecitabine and gemcitabine will have on your tumor. This research is being done because right now there is no curative treatment for this type of cancer. Standard chemotherapy causes the tumor to shrink in 10%-15% of people with unresectable gallbladder or cholangiocarcinoma, but those responses last only 3-6 months. Better therapies are needed to treat patients with this disease. The patient will be asked for permission to submit their tissue samples and blood samples to that they may be studied. Scientist will study their tissue to see if they can predict survival by testing certain aspects of their tumor tissue. If they agree, tumor tissue that is left from the biopsy they have before they register to this study will be used for these tests. The blood sample will be taken before they start treatment. A consent form for use of specimens for research has information about using their tissue for research and asks if they will agree to allow us to keep some of the tissue that is left and use it for future studies.